Commentary: Neoadjuvant immune checkpoint monotherapy for lung cancer: Has the train left the station?

[摘要] In this issue of the Journal, Rusch and colleagues1 report the results of the Lung Cancer Mutation Consortium 3 (LCMC3) trial, the largest neoadjuvant trial of immune checkpoint inhibitor (ICI) monotherapy in patients with resectable stage IB to IIIB non–small cell lung cancer. Within 3 years, the investigators accrued 181 patients across 13 centers who received up to 2 preoperative cycles of the anti-programmed death-ligand 1 blocking antibody atezolizumab. The trial met its primary end point of major pathologic response (MPR), which was observed in 29 out of 143 resected patients (20%) whose tumors did not harbor EGFR mutations or Alk alterations.

[学科分类] 心脏病和心血管学